Ingelheim, Germany: Results presented at the 33rd ECNP Congress from a 12-week, placebo-controlled Phase II trial demonstrated BI 425809 has met its primary endpoint1,2Trial results,...
W Health Ventures, a healthcare focused VC fund that invests in and grows tech-enabled early-stage healthcare companies, hosted an industry discussion in Delhi, with...